Search
Teriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalIt is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersSynonyms: (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidideLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin was approved by the FDA on May 2, 2011[L9557].
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigationalgamma 1 (IgG1). … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa).
Products: EYLIA® SOLUCIÓN PARA INYECCIÓN INTRAVÍTREA, ZALTRAP 100MG/4ML INFUZYONLUK KONSANTRE COZELTI İÇEREN FLAKON, 3 ADETIcosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Categories: Fatty Acids, Omega-3Synonyms: E-EPA, (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl esterArbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Categories: GABA-B Receptor AgonistsEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. … Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity. … It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSynonyms: 4-OH-A, 4-hydroxy-4-androstene-3,17-dioneFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Mixtures: RELVAR® ELLIPTA® 100MCG/25MCG, RELVAR® ELLIPTA ® 200MCG/25MCG POLVO PARA INHALACIÓNCategories: P-glycoprotein inducers, P-glycoprotein substratesAleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects
Categories: Heterocyclic Compounds, 1-Ring